

Amplia Therapeutics Limited

Bioshares Presentation - July 2019

ASX:ATX

Amplifying Immuno-oncology

Notice

The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited ("Amplia") in any jurisdiction. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation contains forward-looking statements which can be identified by the use of words such as "may", "should", "will", "expect", "anticipate", "believe", "estimate", "intend", "scheduled" or "continue" or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Amplia, and its officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.

There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The data and results pertaining to clinical subjects used in this presentation are illustrative of medical conditions and outcomes associated with potential applications of Amplia's acquired product pipeline. Actual results from clinical trials may vary from those shown.

Amplia THERAPEUTICS

Amplia Therapeutics

- A pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors offering therapeutic potential in cancer and fibrosis
- Current focus is on highly selective FAK inhibitors
    - Combinations with immuno-oncology products
    - Wide range of fibrotic diseases



Amplia THERAPEUTICS

Checkpoint Inhibitor Primer

- Many cancers evade detection by the immune system by co-opting negative regulators of the anti-tumour immune response
- One such immunosuppressive action is achieved by tumour upregulation of checkpoint proteins such as PD-L1
- Interaction of PD-L1 with PD-1 blunts the response of cytotoxic lymphocytes
    - PD-L1 and PD-1 are then referred to as ‘checkpoint proteins’
- Antibodies directed at checkpoint proteins block the PD-L1/PD-1 interaction and restore the anti-tumour immune response



Reproduced from National Cancer Institute

Checkpoint Inhibitor Market Growth



Data assimilated from Bristol-Myers Squibb and Merck periodic financial reports

Amplia THERAPEUTICS

The Need



Adapted from
Haslam A, Prasad, V., *JAMA Network Open*. 2019;2(5):e192535

- Although checkpoint inhibitor drugs have revolutionised cancer treatment, complete response rates to these agents are still low
- Only 44% of all cancer patients are eligible to receive these drugs and, of these, only 13% respond completely to therapy
- Why do ~87% of eligible patients not yet fully respond to checkpoint inhibitors?
    - Certain tumours are ‘cold’ and remain invisible to the immune system
    - Checkpoint blockade is not sufficient to overcome the immunosuppressive tumour microenvironment
- Combination therapies are a key frontier

Amplia THERAPEUTICS

Focal Adhesion Kinase – a ‘Bad Actor’ in Cancer

- FAK is upregulated in many cancers and plays multiple roles
  - Involved in cellular adhesion and migration
  - Promotes cancer cell survival and proliferation
  - Contributes to the establishment of an immunosuppressive tumour microenvironment
    - Regulation of immunosuppressive chemokines and cytokines
    - Suppression of the antitumour CD8+ T-cell response
    - Promotes fibrosis, altering the tumour’s physical environment
- FAK ‘buffers’ tumour cells from stress
  - Current theory is that certain tumour types become ‘FAK dependent’



Crystal Structure of FAK

Amplia’s premise

FAK inhibitors will improve the efficacy of front-line cancer immunotherapies by suppressing the tumour-protective properties of FAK

Amplia THERAPEUTICS

Amplia's Therapeutic Focus

- Dual anti-fibrotic and immunomodulatory action of FAK inhibitors may be advantageous in fibrotic cancer
    - Growing case for potential of 'mechanotherapeutics' (including FAK inhibitors) in fibrotic cancers*
- Fibrotic cancers including pancreatic and ovarian cancer
    - Pancreatic cancer has the worst survival outcome of the 21 most common cancers
    - Ovarian cancer ranks fifth in cancer deaths among women

* Pancreatic cancer provides testbed for first mechanotherapeutics. *Nature Biotechnology*, 12th July 2019

Amplia THERAPEUTICS

Amplia's Early Clinical Development Strategy



- Establish safety to support Phase 1 in healthy volunteers

Underway

- Go as fast as possible
- Establish clinical safety baseline
- Confirm FAK engagement

Drug available

- Establish clinical POC
  - Cancer
  - Fibrosis
  - Combinations

Amplia THERAPEUTICS

Amplia's Early Clinical Development Strategy

- Perform first-in-human studies in healthy volunteers to establish a safety baseline
  - Assess safety, tolerability
  - Confirm engagement of FAK
- Use established safety profile as a foundation for multiple combination opportunities
- Advantages:
  - 'Clean' safety data without confounding effects of disease symptoms;
  - Shorter, more predictable costs and timelines;
  - Consistent with recommendations of SITC Combination Therapies Taskforce.

Amplia THERAPEUTICS

High-level Development Plan (18 months)



Phase 1 single ascending dose and multiple ascending dose healthy volunteer study designed to also confirm target (FAK) engagement.

Data will support Phase 2 trials in multiple combinations/therapeutic areas.

Amplia THERAPEUTICS

Competitive Landscape

Agent	Company	Status	Notes
VS-4718 (PND-1186)	Verastem	P1 (various studies)	First generation candidate
BI-853520	Boehringer-Ingelheim	P1 (NCT01335269) & (NCT01905111)	Two trials completed (Aug 14 & Dec 15)
CT-707	Centaurus Pharma	P1 (NCT02695550)	Unknown status. Last update Mar 17. Single site China. Questions about selectivity
GSK-2256098	GSK	P2 (NCT02428270)	Combo with chemo (Trametinib) in pancreatic cancer (n=16). Target completion Dec 19
VS-6063 (PF-04554878)	Verastem	3 x P2 (monotherapy)	1 terminated, 1 completed Apr 17 (?) not reported, 1 recruiting target completion Sep 19
VS-6063	Verastem	P1/2 (NCT02758587)	Combo with Pembrolizumab in several cancers (Target n=59). Target completion Dec 21
VS-6063	Verastem	P1/2 (NCT03287271)	Combo with SOC chemo in ovarian cancer (Target n=90). Target completion Oct 24
VS-6063	Verastem	P2 (NCT03727880)	Combo with Pembrolizumab in pancreatic cancer (Target n=36). Target completion Feb 23

- Established target but little commercial congestion due to lack of highly selective FAK inhibitors
- Clinical development now focused on combo therapy in oncology setting
- Verastem (NASDAQ: VSTM, Market Cap USD $120m) nearest comparator however our molecules are highly differentiated, both in their selectivity and multi-action effect

Amplia THERAPEUTICS

Differentiation of Amplia FAK Assets

- Excellent potency, selectivity and pharmacokinetics
  - AMP945 is a highly selective FAK inhibitor
  - AMP886 is a multi-action molecule that hits two other important cancer pathways – VEGFR3 and FLT3
- Strong intellectual property position
  - Issued patents in all commercially important jurisdictions (exp. 2033/34)
  - Optimised formulation application filed March 2019 with potential to extend IP protection out to 2040

Amplia THERAPEUTICS

Near Term Catalysts - Summary

- Amplia's strategy is to position its assets to maximize opportunities for combination efficacy studies in cancer
    - Fibrosis indications further underpin value
- Multiple near- and mid-term value inflection points
    - Phase 1 trial in healthy volunteers in 2020
    - IND opening Q3 2020
    - Phase 2 ready late 2020
    - Ongoing partner engagement and opportunities to combine with approved products
- Amplia's experienced drug development team is strongly positioned to optimise asset value

Amplia THERAPEUTICS

For further information please contact

Dr John Lambert

Chief Executive Officer

john@ampliatx.com

+61 (0)409 525 259

www.ampliatx.com

Amplia THERAPEUTICS